Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 glasdegib (PF-04449913) in Japanese patients with hematologic malignancies
jRCT2080222383Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of glasdegib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and hematopoietic malignancies (4 arms), sponsored by Pfizer. Started Jan 2014; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)hematopoietic malignancies
Beyond the preview
Go deeper on jRCT2080222383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222383.